Fulcrum Therapeutics, Inc. (FULC) has a good chance at potentially staging a comeback with its other pipeline drug pociredir, which is being developed in a phase 1b study for the treatment of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback